Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/ G724S Mutation

被引：0
|
作者：
Lyu, X. [1 ]
Jiao, T. [1 ]
Yang, S. [1 ]
Yang, S. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
lung adenocarcinoma; targeted therapy; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-08
引用
收藏
页码：S643 / S643
页数：1
相关论文
共 50 条
  • [41] Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
    Wang, X.
    Gao, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S922 - S923
  • [42] Lung Adenocarcinoma with Double Heterozygote EGFR mutation and Combined Resistance: ALK Translocation and EGFR T790M
    Denninghoff, V.
    Wainsztein, V.
    Cuello, M. T.
    Recondo, G.
    Rojas Bilbao, E.
    Avagnina, A.
    Recondo, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S179 - S179
  • [43] Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review
    Hakozaki, Taiki
    Yomota, Makiko
    ONCOTARGETS AND THERAPY, 2019, 12 : 745 - 748
  • [44] Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid
    Theoleyre, Sandrine
    Masson, Ingrid
    Herbreteau, Guillaume
    Vallee, Audrey
    Senellart, Helene
    Denis, Marc G.
    LUNG CANCER, 2017, 114 : 111 - 112
  • [45] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [46] Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
    Iams, W.
    Chae, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2249 - S2250
  • [47] Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report
    Kunimasa, Kei
    Sugimoto, Naotoshi
    Tamiya, Motohiro
    Inoue, Takako
    Kawamura, Takahisa
    Kanzaki, Ryu
    Okami, Jiro
    Nishino, Kazumi
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1137 - 1140
  • [48] Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
    Peng, MuYun
    Wen, QiuYuan
    Wu, Xia
    Yu, FengLei
    Liu, WenLiang
    THORACIC CANCER, 2020, 11 (09) : 2704 - 2708
  • [49] Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
    Makimoto, Go
    Nishi, Tatsuya
    Kawakado, Keita
    Nishimura, Tomoka
    Tamura, Tomoki
    Kudo, Kenichiro
    Kuyama, Shoichi
    INTERNAL MEDICINE, 2020, 59 (17) : 2161 - 2164
  • [50] Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report
    Kei Kunimasa
    Naotoshi Sugimoto
    Motohiro Tamiya
    Takako Inoue
    Takahisa Kawamura
    Ryu Kanzaki
    Jiro Okami
    Kazumi Nishino
    Investigational New Drugs, 2022, 40 : 1137 - 1140
12345